You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Details for Patent: 9,889,118


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,889,118 protect, and when does it expire?

Patent 9,889,118 protects BARHEMSYS and is included in one NDA.

This patent has fifty-two patent family members in twenty-six countries.

Summary for Patent: 9,889,118
Title:Use of amisulpride as an anti-emetic
Abstract: Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
Inventor(s): Gilbert; Julian Clive (Cambridgeshire, GB), Gristwood; Robert William (Cambridge, GB), Cooper; Nicola (Essex, GB), Fox; Gabriel (Cambridgeshire, GB)
Assignee: Acacia Pharma Limited (Cambridgeshire, GB)
Application Number:15/374,174
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 9,889,118

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Acacia BARHEMSYS amisulpride SOLUTION;INTRAVENOUS 209510-001 Feb 26, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING ⤷  Try a Trial
Acacia BARHEMSYS amisulpride SOLUTION;INTRAVENOUS 209510-001 Feb 26, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING ⤷  Try a Trial
Acacia BARHEMSYS amisulpride SOLUTION;INTRAVENOUS 209510-002 Sep 1, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING ⤷  Try a Trial
Acacia BARHEMSYS amisulpride SOLUTION;INTRAVENOUS 209510-002 Sep 1, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,889,118

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom1004020.2Mar 11, 2010

International Family Members for US Patent 9,889,118

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011225898 ⤷  Try a Trial
Brazil 112012022746 ⤷  Try a Trial
Canada 2792392 ⤷  Try a Trial
China 102892407 ⤷  Try a Trial
Cyprus 1115485 ⤷  Try a Trial
Cyprus 1115487 ⤷  Try a Trial
Cyprus 1120170 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.